Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 571-577

  Mhawech Fauceglia, Paulette ^a   Smiraglia, Dominic J ^a   Bshara, Wiam ^a   Andrews, Christopher ^b   Schwaller, Juerg ^c   South, Stacey ^a   Higgs, Donald ^a   Lele, Shashikant ^a   Herrmann, Francois ^d   Odunsi, Kunle ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CPG ISLAND; DISEASE FREE SURVIVAL; DOWN REGULATION; ENDOMETRIUM CARCINOMA; EPIGENETICS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METHYLATION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CELL LINE, TUMOR; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 41549161440     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-0511     Document Type: Article

References (35)

1. Fair WR, Israeli RS, Heston WDW. Prostate-specific membrane antigen. Prostate 1997;32:140-8.
2. Murphy GP, Elgamal A-BA, Su SL, et al. Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 1998;83:2259-69.
3. Gala J-L, Loric S, Guiot Y, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res 2000;6:4049-54.
4. Israeli RS, Powell CT, Corr JG, et al. Expression of prostate specific membrane antigen. Cancer 1994;62:1807-11.
5. Chang SS, Reuter VE, Heston WDW, et al. Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-8.
6. Silver DA, Pellicer I, Fair WR, et al. Prostate specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
7. Burger MJ, Tebay MA, Keith PA, et al. Expression analysis of δ-catenin and prostatic-specific membrane antigen. Their potential as diagnostic markers for prostate cancer. Int J Cancer 2002;100:228-37.
8. Dumas F, Gala JL, Berteau P, et al. Molecular expression of PSMA mRNA and protein in primary renal tumors. Int J Cancer 1999;80:799-803.
9. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. prostate specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology 2007;50:472-83.
10. Pinto JT, Suffoletto BP, Berzin TM, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-51.
11. Ghosh A, Heston DWD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004;91:528-39.
12. Rinker-Schaeffer CW, Hawkins AL, Su L, et al. Localization and physical mapping of the prostate specific membrane antigen (PSM) gene to human chromosome 11. Genomics 1995;30:105-8.
13. Ichikawa T, Ichikawa Y, Dong J, et al. Localization of metastasis suppressor gene (s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 1992;52:486-90.
14. Corr JG, Israeli RS, Huryk RF, Fair WR, Heston WDW. Prostate specific membrane antigen (PSM) expression in orthotopically implanted human prostate cancer cells in nude mice slows tumor growth and metastatic potential [abstract]. J Urol 1994;151:492A.
15. Elgamal AA, Holmes EH, Su SL, et al. Prostate-specific membrane antigen (PSMA): current benefits and future value. Semin Surg Oncol 2000;18:10-6.
16. Solvin SF. Emerging role of immunotherapy in the management of prostate cancer. Oncology (Huntingt) 2007;21:326-33.
17. Sodee DB, Sodee AE, Bakale G. Synergetic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 2007;37:17-28.
18. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubick-Huch RA, Tavassoli FA. Tumors of the uterine corpus. In Tavassoli FA, Devilee P, editors. WHO classification. Lyon: IARC Press; 2003. p. 217-57.
19. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
20. Cirisano FD, Jr., Robboy SJ, Dodge RK, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999;74:385-94.
21. Cirisano FD, Jr., Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55-6.
22. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 2001;6:47-86.
23. Gremer O, Uriev L, Harkovsky T. The significance of the degree of myometrial invasion in patients with stage IB endometrial cancer. Eur J Gynaecol Oncol 2004;25:336-8.
24. Alektiar KM, McKee A, Lin O, et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer? Int J Radiat Oncol Biol Phys 2002;54:79-85.
25. Yasunaga M, Yamasaki F, Tokunaga O, Twasaka T. Endometrial carcinomas with lymph node involvement: novel histopathologic factors for predicting prognosis. Int J Gynecol Pathol 2003;22:341-6.
26. Noss KR, Singal R, Grimes SR. Methylation state of the prostate specific membrane antigen (PSMA) CpG island in prostate cancer cell lines. Anticancer Res 2002;22:1505-12.
27. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4:844-94.
28. Mhawech P, Benz A, Greloz V, et al. Down-regulation of 14-3-3σ in ovary, prostate, and endometrial carcinomas is associated with CpG-methylation. Mod Pathol 2005;18:340-8.
29. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
30. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. J Urol 1998;52:637-40.
31. Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-62.
32. Gala JL, Heusterpreute M, Loric S, et al. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998;44:472-81.
33. Bussaglia E, del Rio E, Matias-Guiu X, et al. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000;31:312-7.
34. Zhou ZC, Dowdy SC, Podratz KC, Jiang S-W. Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol Oncol. In press 2007.
35. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.